News|Articles|May 7, 2024
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
Author(s)PCM Trials
In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Related Content
Trending on Applied Clinical Trials Online
1
Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose
2
ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor
3
Applying Systems Thinking to the Future of Clinical R&D
4
ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN
5